pharma · TTR-mediated Amyloidosis · Hypertension · ALNY
Alnylam Netherlands
Alnylam Netherlands B.V.
Alnylam Netherlands is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker ALNY. Primary therapeutic focus areas include TTR-mediated Amyloidosis, Hypertension, Transthyretin Amyloidosis
Cambridge, USA HQ
2002 Founded
2,826 Employees
Public company Type
ALNY · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2002
- Employees
- 2,826
- Programs
- 84
- Drugs
- 37
- Patents
- 379
cemdisiran
Phase 2 · small molecule · Atypical Hemolytic Uremic Syndrome
cemdisiran for Atypical Hemolytic Uremic Syndrome is a Phase 2 program (small_molecule) at Alnylam Netherlands B.V. with 2 ClinicalTrials.gov record(s).
Internal code Cemdisiran in aHUS
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Alnylam Netherlands B.V.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Atypical Hemolytic Uremic Syndrome
- Status
- terminated
- Trials
- 2